Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow disability progression.

Hansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with ...

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not ...

Low immunoglobulin levels affect nearly 1 in 4 newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) and significantly increase infection risk during treatment.

Patients underwent monitoring of immunoglobulin levels and had nasal swab collected monthly, with viral infections recorded when symptoms such as runny nose, cough, or fever were present.